S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'

Viking Therapeutics (VKTX) Stock Price, News & Analysis

$82.00
-1.34 (-1.61%)
(As of 03/28/2024 ET)
Today's Range
$80.50
$84.70
50-Day Range
$21.37
$94.50
52-Week Range
$8.28
$99.41
Volume
4.33 million shs
Average Volume
9.06 million shs
Market Capitalization
$8.24 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$112.25

Viking Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
36.9% Upside
$112.25 Price Target
Short Interest
Healthy
11.09% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
0.68mentions of Viking Therapeutics in the last 14 days
Based on 44 Articles This Week
Insider Trading
Selling Shares
$9.73 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.10) to ($1.36) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.86 out of 5 stars

Medical Sector

88th out of 939 stocks

Pharmaceutical Preparations Industry

32nd out of 444 stocks

VKTX stock logo

About Viking Therapeutics Stock (NASDAQ:VKTX)

Founded in 2012, Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California. The company is focused on developing novel therapies for metabolic and endocrine disorders, including non-alcoholic steatohepatitis (NASH), hip fracture recovery, and type 2 diabetes. Viking's mission is to bring life-changing treatments to patients with unmet medical needs.

Viking's lead product candidate, VK2809, is a small molecule thyroid beta receptor agonist currently being evaluated in a Phase 2b clinical trial for treating NASH. The company's other product candidates include VK0214, a liver-directed thyroid receptor beta agonist for treating X-linked adrenoleukodystrophy (X-ALD), and VK0612, a novel PPAR-delta agonist for the treatment of type 2 diabetes.

Viking's management team is led by Chief Executive Officer Brian Lian, who joined the company in 2016. Lian has over 25 years of experience in the biotech and pharmaceutical industries, including senior leadership roles at InterMune, Abgenix, and Bristol-Myers Squibb. 

Viking is working hard to grow its revenue. However, the company has yet to turn a profit, reporting a net loss of $68 million in 2022 which increased from 2021's reported $-55 million loss. Viking has also been actively raising capital, recently completing a public offering of common stock.

Viking's current market capitalization is around $1.9 billion, with a price-to-book ratio that aligns with industry peers. Still, some investors see the potential for significant upside if Viking's clinical trials are successful.

Viking's stock price has been volatile over the recent past. The stock has seen a slight uptick recently due to positive news about its drugs in clinical trials. The company's trading volume has been increasing steadily, indicating investor interest.

Viking operates in the highly competitive biotech industry, where companies must navigate complex regulatory environments and rapidly evolving technologies. The NASH market, in particular, is highly competitive, with several large pharmaceutical companies developing therapies for the disease. However, Viking's focus on novel mechanisms of action and expertise in metabolic and endocrine disorders give the company a competitive advantage. Additionally, Viking's partnerships with established biotech companies, such as Ligand Pharmaceuticals and Bayer, provide the company with valuable resources and expertise.

Viking has several potential growth opportunities in the pipeline, including the ongoing Phase 2b clinical trial of VK2809 for treating NASH. If the trial succeeds, Viking could partner with a larger pharmaceutical company to bring the therapy to market. The company's other product candidates, including VK0214 and VK0612, also have the potential to address significant unmet medical needs. Viking has also explored expansion opportunities into new therapeutic areas, such as oncology.

Viking Therapeutics faces a risk from the possibility of regulatory changes affecting the approval of its products. The pharmaceutical industry is heavily regulated, and any changes in regulations or policies could impact Viking's ability to bring its products to market or receive approval for clinical trials. In addition, the company's competitors may also receive approval for similar products, reducing the market share available to Viking.

Risk management is an integral part of any business strategy, and Viking Therapeutics is taking steps to mitigate the risks it faces. The company has a diverse pipeline of products, which helps reduce the impact of any one product failing. Viking is also conducting extensive clinical trials to ensure the safety and efficacy of its products, which could increase the likelihood of approval and reduce the risk of adverse events.

VKTX Stock Price History

VKTX Stock News Headlines

7 Stocks That Will Drive the Weight Loss Drugs Market (VKTX)
The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.
Vivani Medical Surges on its Ozempic-Like Weight-Loss Implant (VKTX)
The Ozempic craze continues to make headlines in the medical sector, and GLP-1 drug stocks such as Vivani Medical continue to surge higher
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Stifel Nicolaus Remains a Buy on Viking Therapeutics (VKTX)
Viking Therapeutics: Buy, Sell, or Hold?
Why Is Viking Therapeutics (VKTX) Stock Up 24% Today?
See More Headlines
Receive VKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/07/2024
Today
3/29/2024
Next Earnings (Estimated)
4/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VKTX
Fax
N/A
Employees
27
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$112.25
High Stock Price Target
$138.00
Low Stock Price Target
$80.00
Potential Upside/Downside
+36.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$-85,890,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.48 per share

Miscellaneous

Free Float
96,067,000
Market Cap
$8.24 billion
Optionable
Optionable
Beta
1.06
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Brian Lian Ph.D. (Age 58)
    President, CEO & Director
    Comp: $965.12k
  • Mr. Gregory S. Zante (Age 53)
    Chief Financial Officer
    Comp: $603.5k
  • Ms. Marianne Mancini (Age 59)
    Chief Operating Officer
    Comp: $633.3k
  • Mr. Michael Morneau (Age 59)
    Vice President of Finance & Administration
    Comp: $375.33k
  • Dr. Geoffrey E. Barker Ph.D.
    Senior Vice President of Pharmaceutical Development

VKTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Viking Therapeutics stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VKTX shares.
View VKTX analyst ratings
or view top-rated stocks.

What is Viking Therapeutics' stock price target for 2024?

10 analysts have issued twelve-month price objectives for Viking Therapeutics' stock. Their VKTX share price targets range from $80.00 to $138.00. On average, they anticipate the company's stock price to reach $112.25 in the next year. This suggests a possible upside of 36.9% from the stock's current price.
View analysts price targets for VKTX
or view top-rated stocks among Wall Street analysts.

How have VKTX shares performed in 2024?

Viking Therapeutics' stock was trading at $18.61 at the beginning of 2024. Since then, VKTX stock has increased by 340.6% and is now trading at $82.00.
View the best growth stocks for 2024 here
.

When is Viking Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our VKTX earnings forecast
.

How were Viking Therapeutics' earnings last quarter?

Viking Therapeutics, Inc. (NASDAQ:VKTX) announced its quarterly earnings results on Wednesday, February, 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.25). During the same quarter in the previous year, the company earned ($0.26) earnings per share.

What ETFs hold Viking Therapeutics' stock?
What other stocks do shareholders of Viking Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), SCYNEXIS (SCYX), Amarin (AMRN), Advanced Micro Devices (AMD), Verastem (VSTM), Energy Transfer (ET) and Inovio Pharmaceuticals (INO).

When did Viking Therapeutics IPO?

Viking Therapeutics (VKTX) raised $20 million in an initial public offering (IPO) on Wednesday, April 29th 2015. The company issued 2,500,000 shares at $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager.

Who are Viking Therapeutics' major shareholders?

Viking Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.36%), Vanguard Group Inc. (5.36%), Viking Global Investors LP (5.12%), Wasatch Advisors LP (1.27%), Goldman Sachs Group Inc. (1.11%) and Goldman Sachs Group Inc. (1.11%). Insiders that own company stock include Brian Lian, Charles A Rowland Jr, Greg Zante, Lawson Macartney, Marianna Mancini, Matthew W Foehr and Sarah Kathryn Rouan.
View institutional ownership trends
.

How do I buy shares of Viking Therapeutics?

Shares of VKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VKTX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners